MX390671B - Composicion de suspension oftalmica. - Google Patents
Composicion de suspension oftalmica.Info
- Publication number
- MX390671B MX390671B MX2017009699A MX2017009699A MX390671B MX 390671 B MX390671 B MX 390671B MX 2017009699 A MX2017009699 A MX 2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A MX 390671 B MX390671 B MX 390671B
- Authority
- MX
- Mexico
- Prior art keywords
- ophthalmic
- composition
- suspension
- ophthalmic suspension
- âμm
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940100654 ophthalmic suspension Drugs 0.000 title 1
- 239000000725 suspension Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000375 suspending agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una suspensión incluye un ingrediente activo oftálmico suspendido en un vehículo de formulación que incluye un agente de suspensión y un derivado de celulosa no iónico. El agente activo oftálmico está presente como partículas que tienen Dv90 <5 µm y Dv50 <1 µm. La suspensión se puede administrar a un paciente para tratar una afección inflamatoria oftálmica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107696P | 2015-01-26 | 2015-01-26 | |
| PCT/US2016/014872 WO2016123079A1 (en) | 2015-01-26 | 2016-01-26 | Ophthalmic suspension composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017009699A MX2017009699A (es) | 2017-10-23 |
| MX390671B true MX390671B (es) | 2025-03-21 |
Family
ID=55359733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009699A MX390671B (es) | 2015-01-26 | 2016-01-26 | Composicion de suspension oftalmica. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10596107B2 (es) |
| EP (5) | EP4082531B1 (es) |
| JP (1) | JP2018507252A (es) |
| KR (1) | KR102538370B1 (es) |
| CN (1) | CN107427464B (es) |
| AU (3) | AU2016211745A1 (es) |
| BR (1) | BR112017016016B1 (es) |
| CA (1) | CA2975106A1 (es) |
| ES (5) | ES2966595T3 (es) |
| HU (5) | HUE066045T2 (es) |
| MX (1) | MX390671B (es) |
| PL (5) | PL3250185T3 (es) |
| PT (3) | PT4268850T (es) |
| SI (1) | SI4268850T1 (es) |
| WO (1) | WO2016123079A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016211745A1 (en) | 2015-01-26 | 2017-08-31 | Bausch & Lomb Incorporated | Ophthalmic suspension composition |
| US11000475B2 (en) | 2015-10-16 | 2021-05-11 | Sun Pharma Advanced Research Company Limited | Ophthalmic solution of difluprednate |
| PL3245988T3 (pl) | 2016-05-18 | 2024-05-27 | Sonikure Holdings Limited | Układ do przeztwardówkowego podawania leków wspomaganego ultradźwiękami |
| US11344562B2 (en) | 2017-08-15 | 2022-05-31 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
| WO2020061249A2 (en) * | 2018-09-21 | 2020-03-26 | Ps Therapies Ltd. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
| JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| EP3924345A1 (en) * | 2019-02-15 | 2021-12-22 | Novartis AG | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof |
| EP4013443A4 (en) * | 2019-08-18 | 2023-10-04 | IVIEW Therapeutics (Zhuhai) Co., Ltd. | IN-SITU GEL-CONTAINING CYCLOSPORINE MICELLARS AS A SYSTEM FOR THE DELAYED RELEASE OF OPHTHALMIC ACTIVE INGREDIENTS |
| KR102271247B1 (ko) * | 2020-11-04 | 2021-06-30 | 삼천당제약주식회사 | 안과용 현탁액 조성물의 제조방법 |
| CN115887372A (zh) * | 2022-10-25 | 2023-04-04 | 苏州欧康维视生物科技有限公司 | 丙酸氟替卡松混悬液及其制备方法 |
| CN115554238A (zh) * | 2022-10-25 | 2023-01-03 | 苏州欧康维视生物科技有限公司 | 眼用混悬液及其制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| US4540930A (en) | 1983-09-12 | 1985-09-10 | Wisconsin Alumni Research Foundation | Plywheel-powered mobile X-ray apparatus |
| EP0501523B1 (en) | 1983-11-14 | 1997-04-09 | Columbia Laboratories, Inc. | Bioadhesive compositions |
| NZ226171A (en) | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| US5192535A (en) | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
| IE63392B1 (en) | 1988-02-08 | 1995-04-19 | Insite Vision Inc | Ophthalmic suspensions |
| US5124154A (en) | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| CA2134376C (en) | 1993-12-20 | 2001-10-23 | Haresh G. Bhagat | Combinations of polymers for use in physiological tear compositions |
| AU684115B2 (en) * | 1993-12-27 | 1997-12-04 | Mitsubishi Chemical Corporation | Ophthalmic suspension containing diflupredonate |
| GB9718568D0 (en) * | 1997-09-03 | 1997-11-05 | Chauvin Pharmaceuticals Limite | Compositions |
| TWI227143B (en) | 1999-12-15 | 2005-02-01 | Guo-Jiun Sung | In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method |
| AR033151A1 (es) * | 2001-04-12 | 2003-12-03 | Sucampo Pharmaceuticals Inc | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares |
| US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
| WO2004006959A1 (en) * | 2002-07-16 | 2004-01-22 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
| CA2839928C (en) * | 2003-06-13 | 2016-10-04 | Alcon, Inc. | Ophthalmic compositions containing a synergistic combination of two polymers |
| US20050197303A1 (en) | 2003-10-31 | 2005-09-08 | Bausch & Lomb Incorporated | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
| US20050182039A1 (en) * | 2004-02-13 | 2005-08-18 | Bausch & Lomb Incorporated | Use of Loteprednol etabonate for the treatment of dry eye |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| US7919483B2 (en) | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
| US20120028947A1 (en) | 2005-11-14 | 2012-02-02 | Erning Xia | Ophthalmic Compositions |
| WO2007058935A2 (en) | 2005-11-14 | 2007-05-24 | Bausch & Lomb Incorporated | Ophthalmic composition for dry eye therapy |
| US20100234336A1 (en) | 2005-11-14 | 2010-09-16 | Erning Xia | Ophthalmic Compositions |
| US8846770B2 (en) * | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| CN101966143A (zh) | 2009-07-28 | 2011-02-09 | 胡容峰 | 加替沙星温度及pH敏感眼用凝胶的制备与应用 |
| SI2506831T1 (sl) | 2009-12-03 | 2014-01-31 | Alcon Research, Ltd. | Suspenzije nanodelcev, ki vsebujejo karbonilvinilni polimer |
| AU2012312816A1 (en) | 2011-09-22 | 2014-04-24 | Bausch & Lomb Incorporated | Ophthalmic gel compositions |
| EP4008355A1 (en) | 2012-05-03 | 2022-06-08 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| JP6285419B2 (ja) | 2012-05-08 | 2018-02-28 | ニコックス アフサァルミィクス、 インコーポレイテッドＮｉｃｏｘ Ｏｐｈｔｈａｌｍｉｃｓ， Ｉｎｃ． | 疎水性治療剤の調製物、製造方法およびその使用 |
| US8765725B2 (en) * | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| CN104203217B (zh) * | 2012-05-11 | 2017-02-15 | 株式会社活效制药 | 有机化合物纳米粉体的制造方法 |
| US20160051503A1 (en) | 2012-08-31 | 2016-02-25 | Bausch & Lomb Incorporated | Ophthalmic compositions with omega-3 fatty acids |
| US20150190407A1 (en) | 2014-01-07 | 2015-07-09 | Insite Vision Incorporated | Methods for treatment of postoperative inflammation with reduced intraocular pressure |
| AU2015288644B2 (en) | 2014-07-11 | 2017-12-14 | Fujifilm Corporation | Aqueous ophthalmic composition |
| WO2016006701A1 (ja) | 2014-07-11 | 2016-01-14 | 富士フイルム株式会社 | 眼科用水性組成物の製造方法及び眼科用水性組成物 |
| US10172852B2 (en) | 2014-07-28 | 2019-01-08 | Sun Pharma Advanced Research Company Ltd. | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug |
| AU2016211745A1 (en) | 2015-01-26 | 2017-08-31 | Bausch & Lomb Incorporated | Ophthalmic suspension composition |
-
2016
- 2016-01-26 AU AU2016211745A patent/AU2016211745A1/en not_active Abandoned
- 2016-01-26 CA CA2975106A patent/CA2975106A1/en not_active Abandoned
- 2016-01-26 SI SI201631905T patent/SI4268850T1/sl unknown
- 2016-01-26 PT PT231969387T patent/PT4268850T/pt unknown
- 2016-01-26 US US15/006,525 patent/US10596107B2/en active Active
- 2016-01-26 HU HUE22175139A patent/HUE066045T2/hu unknown
- 2016-01-26 ES ES22175139T patent/ES2966595T3/es active Active
- 2016-01-26 CN CN201680016825.XA patent/CN107427464B/zh active Active
- 2016-01-26 HU HUE18209003A patent/HUE048564T2/hu unknown
- 2016-01-26 WO PCT/US2016/014872 patent/WO2016123079A1/en not_active Ceased
- 2016-01-26 PL PL16704744T patent/PL3250185T3/pl unknown
- 2016-01-26 ES ES18209003T patent/ES2787039T3/es active Active
- 2016-01-26 ES ES20166312T patent/ES2924645T3/es active Active
- 2016-01-26 KR KR1020177023453A patent/KR102538370B1/ko active Active
- 2016-01-26 EP EP22175139.9A patent/EP4082531B1/en active Active
- 2016-01-26 JP JP2017558359A patent/JP2018507252A/ja active Pending
- 2016-01-26 PL PL23196938.7T patent/PL4268850T3/pl unknown
- 2016-01-26 ES ES23196938T patent/ES3031414T3/es active Active
- 2016-01-26 PL PL20166312.7T patent/PL3721868T3/pl unknown
- 2016-01-26 PL PL22175139.9T patent/PL4082531T3/pl unknown
- 2016-01-26 HU HUE16704744A patent/HUE041945T2/hu unknown
- 2016-01-26 BR BR112017016016-1A patent/BR112017016016B1/pt active IP Right Grant
- 2016-01-26 EP EP16704744.8A patent/EP3250185B1/en not_active Revoked
- 2016-01-26 EP EP23196938.7A patent/EP4268850B1/en active Active
- 2016-01-26 EP EP20166312.7A patent/EP3721868B2/en active Active
- 2016-01-26 ES ES16704744T patent/ES2704125T3/es active Active
- 2016-01-26 HU HUE20166312A patent/HUE059639T2/hu unknown
- 2016-01-26 HU HUE23196938A patent/HUE071679T2/hu unknown
- 2016-01-26 PL PL18209003T patent/PL3470059T3/pl unknown
- 2016-01-26 PT PT221751399T patent/PT4082531T/pt unknown
- 2016-01-26 EP EP18209003.5A patent/EP3470059B1/en active Active
- 2016-01-26 PT PT201663127T patent/PT3721868T/pt unknown
- 2016-01-26 MX MX2017009699A patent/MX390671B/es unknown
-
2020
- 2020-03-23 US US16/826,366 patent/US11534395B2/en active Active
-
2021
- 2021-05-12 AU AU2021203027A patent/AU2021203027B2/en active Active
-
2022
- 2022-12-21 US US18/086,286 patent/US20230140895A1/en active Pending
-
2023
- 2023-10-12 AU AU2023248145A patent/AU2023248145B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390671B (es) | Composicion de suspension oftalmica. | |
| MX384021B (es) | Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones. | |
| EP4374851A3 (en) | Ophthalmic composition for treatment of dry eye disease | |
| PH12019501902A1 (en) | Ocular formulations for drug-delivery to the posterior segment of the eye | |
| BR112016022607B8 (pt) | Pó e método para aprimorar a aplicação tópica de minoxidil | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| EP4279064A3 (en) | Drug delivery from hydrogels | |
| BR112016010067A2 (pt) | partícula de polímero e método de preparação | |
| MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
| BR112018009644A2 (pt) | micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície | |
| NZ719185A (en) | Crystalline forms of therapeutic compounds and uses thereof | |
| CL2017000120A1 (es) | Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares | |
| MX2021006070A (es) | Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo. | |
| MX2016005764A (es) | Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. | |
| PH12019501999A1 (en) | Pyrazole derivatives as bromodomain inhibitors | |
| MX2021004766A (es) | Composiciones multifásicas. | |
| MY183106A (en) | Fine dry particulate retinoid active agent compostions and topical formulations including the same | |
| BR112015023205A2 (pt) | composições e métodos para formulações de alfavírus vivo atenuado | |
| WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 | |
| MX2016009475A (es) | Composiciones efectivas contra la conjuntivitis viral. | |
| MX2018003799A (es) | Nueva composicion oftalmica que contiene rebamipida y metodo para prepararla. | |
| BR112016015281A8 (pt) | uso de um filtro em linha intravenoso, e método para preparação de um conjunto de infusão | |
| BR112015021000A2 (pt) | composição de uma distribuição liberação prolongada e método de estabilizar proteínas durante o processo de fabricação | |
| EP2962691A4 (en) | AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE POSTERIOR PART OF THE IL CONTAINING A TETRAHYDROPYRANYLAMINOCYCLOPENTYLCARBONYLTETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS ACTIVE INGREDIENT | |
| TH153186A (th) | สูตรผสมชนิดฉีดได้ |